Aim: To review the initial effectiveness of bovine lipid extract surfactant (BLES) for the treatment of respiratory distress syndrome in preterm infants.
| INTRODUCTION
Surfactant replacement therapy reduces mortality and morbidity in preterm infants with respiratory distress syndrome (RDS). [1] [2] [3] [4] [5] There are 2 types of surfactants: animal derived and protein-free synthetic. Although both surfactant types are effective in the treatment and prevention of RDS, meta-analyses have reported early improvement in ventilator support, improved mortality rates, and reduced rates of pneumothoraces with treatment with animalderived surfactants, compared with synthetic products. 6 Animalderived surfactants differ in their phospholipids, surfactant proteins B and C, and plasmalogens composition, as well as their viscosity and volume adminstration. 7, 8 While numerous randomized controlled trials have compared different animal-derived preparations, it remains unclear whether significant differences in clinical outcomes exist among them. 5, 9 Bovine lipid extract surfactant (BLES Biochemicals, London, Canada) is commonly used to treat RDS in premature infants in neonatal intensive care units (NICUs) across Canada, India, South Africa, Iran, Saudi Arabia, Bolivia, and Chile. It is a natural extract of bovine pulmonary surfactant, 9,10 containing 1% SP-B and SP-C and a phospholipid concentration of 27 mg/mL. Despite the popular use of BLES, there are limited published trials for its use in the treatment of RDS in preterm infants. 11, 12 To our knowledge, there have not been -week gestation (group 3). Infants born ≥37 0 -week gestation who received BLES therapy were excluded from the study.
| Statistical analysis
The statistical analysis was performed using SPSS v.24 (IBM Corp, Armonk, New York). The data were presented as mean ± standard deviation (SD), median ± interquartile range (IQR), and number of infants (%). Comparisons between gestational age subgroups were evaluated using Kruskal-Wallis test. Statistical significance was defined as a P value < .05.
The study was approved by the Research Ethics Board at Western
University, London, Ontario, Canada. Individual signed consent is not required to be obtained from patients/guardians for retrospective data/chart review, according to the Research Ethics Board guidelines.
The data were extracted anonymously, with no identifiers. All parents are made aware on admission that our institution is a teaching/academic hospital and that their infant's data may be used for research.
| RESULTS

Ninety-eight infants born between 23
0 -and 36 6 -week gestation with a diagnosis of RDS were treated with BLES during the study period ( Figure 1 ). Twenty-one infants were excluded in the initial analysis.
Sixteen infants had incomplete data collected. A retrospective review of our data found that 12% (10/ 
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